NYSE:MED

Medifast Stock Forecast, Price & News

$289.49
-0.90 (-0.31 %)
(As of 06/11/2021 12:00 AM ET)
Add
Compare
Today's Range
$286.13
$294.42
50-Day Range
$217.95
$332.25
52-Week Range
$102.22
$336.99
Volume129,381 shs
Average Volume126,255 shs
Market Capitalization$3.40 billion
P/E Ratio27.34
Dividend Yield1.96%
Beta1.44
30 days | 90 days | 365 days | Advanced Chart
Receive MED News and Ratings via Email

Sign-up to receive the latest news and ratings for Medifast and its competitors with MarketBeat's FREE daily newsletter.


Medifast logo

About Medifast

Medifast, Inc., through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products in the United States and the Asia-Pacific. It offers bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, puddings, soft serves, shakes, smoothies, soft bakes, and soups under the Medifast, OPTAVIA, Thrive by Medifast, Optimal Health by Take Shape for Life, and Flavors of Home brands. The company markets its products through point of sale transactions over ecommerce platform and its franchisee system. Medifast, Inc. was founded in 1980 and is headquartered in Baltimore, Maryland.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.33 out of 5 stars

Consumer Staples Sector

18th out of 310 stocks

Miscellaneous Food Preparations & Kindred Products Industry

1st out of 10 stocks

Analyst Opinion: 2.5Community Rank: 2.5Dividend Strength: 2.5Insider Behavior: 1.7Valuation: 2.5 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Medifast (NYSE:MED) Frequently Asked Questions

Is Medifast a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medifast in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Medifast stock.
View analyst ratings for Medifast
or view top-rated stocks.

What stocks does MarketBeat like better than Medifast?

Wall Street analysts have given Medifast a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Medifast wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Medifast's next earnings date?

Medifast is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Medifast
.

How were Medifast's earnings last quarter?

Medifast, Inc. (NYSE:MED) issued its quarterly earnings results on Tuesday, May, 4th. The specialty retailer reported $3.46 earnings per share for the quarter, topping the Zacks' consensus estimate of $2.72 by $0.74. The specialty retailer earned $340.70 million during the quarter, compared to analysts' expectations of $279.12 million. Medifast had a net margin of 11.44% and a trailing twelve-month return on equity of 85.97%. Medifast's revenue was up 90.9% on a year-over-year basis.
View Medifast's earnings history
.

How has Medifast's stock price been impacted by Coronavirus (COVID-19)?

Medifast's stock was trading at $70.44 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MED stock has increased by 311.0% and is now trading at $289.49.
View which stocks have been most impacted by COVID-19
.

How often does Medifast pay dividends? What is the dividend yield for Medifast?

Medifast announced a quarterly dividend on Thursday, June 3rd. Shareholders of record on Tuesday, June 22nd will be paid a dividend of $1.42 per share on Friday, August 6th. This represents a $5.68 dividend on an annualized basis and a yield of 1.96%. The ex-dividend date is Monday, June 21st.
View Medifast's dividend history
.

Is Medifast a good dividend stock?

Medifast pays an annual dividend of $5.68 per share and currently has a dividend yield of 1.96%. Medifast does not yet have a strong track record of dividend growth. The dividend payout ratio of Medifast is 62.14%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Medifast will have a dividend payout ratio of 37.77% next year. This indicates that Medifast will be able to sustain or increase its dividend.
View Medifast's dividend history.

What guidance has Medifast issued on next quarter's earnings?

Medifast issued an update on its FY 2021 earnings guidance on Tuesday, May, 25th. The company provided EPS guidance of 12.690-14.140 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $11.110. The company issued revenue guidance of $1.40 billion-$1.48 billion, compared to the consensus revenue estimate of $1.19 billion.

What price target have analysts set for MED?

3 Wall Street analysts have issued 1-year target prices for Medifast's shares. Their forecasts range from $265.00 to $400.00. On average, they anticipate Medifast's share price to reach $353.33 in the next twelve months. This suggests a possible upside of 22.1% from the stock's current price.
View analysts' price targets for Medifast
or view top-rated stocks among Wall Street analysts.

Who are Medifast's key executives?

Medifast's management team includes the following people:
  • Mr. Daniel R. Chard, Exec. Chairman & CEO (Age 56, Pay $2.68M)
  • Mr. James P. Maloney, Chief Financial Officer (Age 53, Pay $694.62k)
  • Mr. William M. Baker IV, Exec. VP of Information Technology (Age 49, Pay $729.77k)
  • Mr. Anthony E. Tyree, Chief Marketing Officer (Age 55, Pay $893.8k)
  • Mr. Nicholas M. Johnson, Pres of Coach & Client Experience (Age 41, Pay $861.94k)
  • Mr. Stephen K. Johnson, VP of Fin. & Chief Accounting Officer (Age 41)
  • Mr. Jason L. Groves, Exec. VP, Gen. Counsel & Corp. Sec. (Age 50)
  • Ms. Claudia C. Greninger, Exec. VP of HR (Age 48)
  • Ms. Lauren Walker, Exec. VP of Supply Chain Operations (Age 54)

What is Daniel Chard's approval rating as Medifast's CEO?

44 employees have rated Medifast CEO Daniel Chard on Glassdoor.com. Daniel Chard has an approval rating of 93% among Medifast's employees. This puts Daniel Chard in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Medifast's key competitors?

What other stocks do shareholders of Medifast own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medifast investors own include NVIDIA (NVDA), Alibaba Group (BABA), AbbVie (ABBV), The Home Depot (HD), The Boeing (BA), Johnson & Johnson (JNJ), Intel (INTC), Cisco Systems (CSCO), AT&T (T) and Exxon Mobil (XOM).

What is Medifast's stock symbol?

Medifast trades on the New York Stock Exchange (NYSE) under the ticker symbol "MED."

Who are Medifast's major shareholders?

Medifast's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (15.42%), Renaissance Technologies LLC (7.60%), Dimensional Fund Advisors LP (3.24%), Bank of New York Mellon Corp (1.83%), Principal Financial Group Inc. (1.72%) and Principal Financial Group Inc. (1.72%). Company insiders that own Medifast stock include Jeffrey J Brown, Michael C Macdonald and Scott Schlackman.
View institutional ownership trends for Medifast
.

Which major investors are selling Medifast stock?

MED stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Arrowstreet Capital Limited Partnership, Schroder Investment Management Group, Ameriprise Financial Inc., Dimensional Fund Advisors LP, Landscape Capital Management L.L.C., Victory Capital Management Inc., and Man Group plc. Company insiders that have sold Medifast company stock in the last year include Michael C Macdonald, and Scott Schlackman.
View insider buying and selling activity for Medifast
or view top insider-selling stocks.

Which major investors are buying Medifast stock?

MED stock was purchased by a variety of institutional investors in the last quarter, including Prudential Financial Inc., BlackRock Inc., Millennium Management LLC, Castleark Management LLC, Lombard Odier Asset Management USA Corp, Squarepoint Ops LLC, Geode Capital Management LLC, and BI Asset Management Fondsmaeglerselskab A S.
View insider buying and selling activity for Medifast
or or view top insider-buying stocks.

How do I buy shares of Medifast?

Shares of MED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Medifast's stock price today?

One share of MED stock can currently be purchased for approximately $289.49.

How much money does Medifast make?

Medifast has a market capitalization of $3.40 billion and generates $934.84 million in revenue each year. The specialty retailer earns $102.86 million in net income (profit) each year or $9.14 on an earnings per share basis.

How many employees does Medifast have?

Medifast employs 713 workers across the globe.

What is Medifast's official website?

The official website for Medifast is www.medifast1.com.

Where are Medifast's headquarters?

Medifast is headquartered at 100 International Drive, Baltimore MD, 21202.

How can I contact Medifast?

Medifast's mailing address is 100 International Drive, Baltimore MD, 21202. The specialty retailer can be reached via phone at 410-581-8042 or via email at [email protected]


This page was last updated on 6/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.